vs
香港置地（LAND）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
香港置地的季度营收约是REGENXBIO Inc.的1.4倍（$41.5M vs $30.3M），香港置地净利率更高（10.2% vs -221.3%，领先231.5%），香港置地同比增速更快（96.5% vs 43.0%），过去两年香港置地的营收复合增速更高（43.1% vs 39.4%）
香港置地是一家专注于房地产投资、管理及开发的集团，在亚洲各地布局商业与住宅地产业务。目前集团在亚洲持有并运营约85万平方米的写字楼及商业零售物业，核心布局中国香港与新加坡两地，其中香港中环的商业物业规模居当地首位，新加坡则主要通过合资持有约16.5万平方米的写字楼空间。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
LAND vs RGNX — 直观对比
营收规模更大
LAND
是对方的1.4倍
$30.3M
营收增速更快
LAND
高出53.5%
43.0%
净利率更高
LAND
高出231.5%
-221.3%
两年增速更快
LAND
近两年复合增速
39.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $41.5M | $30.3M |
| 净利润 | $4.2M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | — | -190.0% |
| 净利率 | 10.2% | -221.3% |
| 营收同比 | 96.5% | 43.0% |
| 净利润同比 | 680.0% | -31.2% |
| 每股收益（稀释后） | $-0.05 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LANDRGNX
| Q4 25 | $41.5M | $30.3M | ||
| Q3 25 | $17.8M | $29.7M | ||
| Q2 25 | $12.3M | $21.4M | ||
| Q1 25 | $16.8M | $89.0M | ||
| Q4 24 | $21.1M | $21.2M | ||
| Q3 24 | $22.6M | $24.2M | ||
| Q2 24 | $21.3M | $22.3M | ||
| Q1 24 | $20.3M | $15.6M |
净利润LANDRGNX
| Q4 25 | $4.2M | $-67.1M | ||
| Q3 25 | $2.1M | $-61.9M | ||
| Q2 25 | $-7.9M | $-70.9M | ||
| Q1 25 | $15.1M | $6.1M | ||
| Q4 24 | $540.0K | $-51.2M | ||
| Q3 24 | $6.0K | $-59.6M | ||
| Q2 24 | $-823.0K | $-53.0M | ||
| Q1 24 | $13.6M | $-63.3M |
毛利率LANDRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率LANDRGNX
| Q4 25 | — | -190.0% | ||
| Q3 25 | — | -176.3% | ||
| Q2 25 | — | -296.3% | ||
| Q1 25 | — | 13.6% | ||
| Q4 24 | — | -242.1% | ||
| Q3 24 | — | -256.6% | ||
| Q2 24 | — | -251.3% | ||
| Q1 24 | — | -408.8% |
净利率LANDRGNX
| Q4 25 | 10.2% | -221.3% | ||
| Q3 25 | 11.7% | -208.3% | ||
| Q2 25 | -64.1% | -331.8% | ||
| Q1 25 | 89.9% | 6.8% | ||
| Q4 24 | 2.6% | -241.3% | ||
| Q3 24 | 0.0% | -246.3% | ||
| Q2 24 | -3.9% | -237.7% | ||
| Q1 24 | 67.0% | -405.4% |
每股收益（稀释后）LANDRGNX
| Q4 25 | $-0.05 | $-1.30 | ||
| Q3 25 | $-0.11 | $-1.20 | ||
| Q2 25 | $-0.38 | $-1.38 | ||
| Q1 25 | $0.25 | $0.12 | ||
| Q4 24 | $-0.15 | $-0.99 | ||
| Q3 24 | $-0.16 | $-1.17 | ||
| Q2 24 | $-0.19 | $-1.05 | ||
| Q1 24 | $0.21 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $27.2M | $230.1M |
| 总债务越低越好 | $473.6M | — |
| 股东权益账面价值 | $670.3M | $102.7M |
| 总资产 | $1.2B | $453.0M |
| 负债/权益比越低杠杆越低 | 0.71× | — |
8季度趋势，按日历期对齐
现金及短期投资LANDRGNX
| Q4 25 | $27.2M | $230.1M | ||
| Q3 25 | $11.3M | $274.2M | ||
| Q2 25 | $30.5M | $323.3M | ||
| Q1 25 | $42.9M | $267.9M | ||
| Q4 24 | $18.3M | $234.7M | ||
| Q3 24 | $13.2M | $255.5M | ||
| Q2 24 | $49.8M | $290.4M | ||
| Q1 24 | $51.6M | $338.7M |
总债务LANDRGNX
| Q4 25 | $473.6M | — | ||
| Q3 25 | $480.4M | — | ||
| Q2 25 | $496.4M | — | ||
| Q1 25 | $498.8M | — | ||
| Q4 24 | $527.5M | — | ||
| Q3 24 | $530.7M | — | ||
| Q2 24 | $549.4M | — | ||
| Q1 24 | $552.2M | — |
股东权益LANDRGNX
| Q4 25 | $670.3M | $102.7M | ||
| Q3 25 | $661.8M | $161.5M | ||
| Q2 25 | $670.1M | $213.7M | ||
| Q1 25 | $689.9M | $274.2M | ||
| Q4 24 | $687.2M | $259.7M | ||
| Q3 24 | $691.2M | $301.4M | ||
| Q2 24 | $708.5M | $348.3M | ||
| Q1 24 | $723.3M | $390.7M |
总资产LANDRGNX
| Q4 25 | $1.2B | $453.0M | ||
| Q3 25 | $1.2B | $525.2M | ||
| Q2 25 | $1.3B | $581.0M | ||
| Q1 25 | $1.3B | $490.9M | ||
| Q4 24 | $1.3B | $466.0M | ||
| Q3 24 | $1.3B | $519.1M | ||
| Q2 24 | $1.4B | $569.4M | ||
| Q1 24 | $1.4B | $629.2M |
负债/权益比LANDRGNX
| Q4 25 | 0.71× | — | ||
| Q3 25 | 0.73× | — | ||
| Q2 25 | 0.74× | — | ||
| Q1 25 | 0.72× | — | ||
| Q4 24 | 0.77× | — | ||
| Q3 24 | 0.77× | — | ||
| Q2 24 | 0.78× | — | ||
| Q1 24 | 0.76× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $7.0M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | 1.66× | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流LANDRGNX
| Q4 25 | $7.0M | $-52.3M | ||
| Q3 25 | $-12.0M | $-56.0M | ||
| Q2 25 | $3.9M | $-49.3M | ||
| Q1 25 | $4.5M | $33.6M | ||
| Q4 24 | $29.5M | $-31.6M | ||
| Q3 24 | $-1.4M | $-40.5M | ||
| Q2 24 | $15.9M | $-45.5M | ||
| Q1 24 | $3.4M | $-55.5M |
自由现金流LANDRGNX
| Q4 25 | — | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率LANDRGNX
| Q4 25 | — | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | — | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度LANDRGNX
| Q4 25 | — | 1.7% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | 3.6% |
现金转化率LANDRGNX
| Q4 25 | 1.66× | — | ||
| Q3 25 | -5.77× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.30× | 5.53× | ||
| Q4 24 | 54.72× | — | ||
| Q3 24 | -227.83× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.25× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAND
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
